Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.80 |
| ▸ | AR | P10275 | 3/20 | 0.80 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.65 |
| ▸ | BCHE | P06276 | 1/20 | 0.61 |
| ▸ | GUSB | P08236 | 1/20 | 0.61 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.61 |
| ▸ | ACHE | P22303 | 1/20 | 0.59 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5084427 | 1.00 | MAOB (0.80) | MAOBARNR1H4ALDH1A1LMNA | |
| SCHEMBL1764951 | 0.90 | NFE2L2 (0.70) | MAOBARNR1H4ALDH1A1LMNA | |
| SCHEMBL20340323 | 0.89 | MAOB (0.71) | MAOBARNR1H4ALDH1A1LMNA | |
| SCHEMBL5084274 | 0.89 | AR (1.00) | MAOBARNR1H4ALDH1A1LMNA | |
| SCHEMBL30807180 | 0.89 | AR (1.00) | MAOBARNR1H4ALDH1A1LMNA | |
| SCHEMBL5084268 | 0.89 | AR (1.00) | MAOBARNR1H4ALDH1A1LMNA | |
| SCHEMBL4864045 | 0.89 | NFE2L2 (0.72) | MAOBARNR1H4ALDH1A1LMNA | |
| SCHEMBL5138170 | 0.88 | MAOB (0.82) | MAOBARNR1H4ALDH1A1LMNA | |
| SCHEMBL5138171 | 0.88 | MAOB (0.82) | MAOBARNR1H4ALDH1A1LMNA | |
| SCHEMBL634205 | 0.86 | NR1H4 (0.79) | MAOBARNR1H4ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106831375-B | Chalcone compound with anti-tumor activity and preparation method and application thereof | 哈尔滨医科大学 | 2020-11-13 | — | — | CN | claimed |
| CN-109890378-A | FOXO1 activity-inhibiting composition | 三得利控股株式会社 | 2019-06-14 | — | — | CN | claimed |
| CN-109890376-A | Composition is used in PGC-1 α activation | 三得利控股株式会社 | 2019-06-14 | — | — | CN | claimed |
| CN-117999099-A | Compositions for inhibiting angiotensin converting enzyme 2 (ACE 2) and/or TMPRSS2 expression | 仿生技术支持有限公司 | 2024-05-07 | — | — | CN | disclosed |
| WO-2022163852-A1 | COMPOSITION FOR INHIBITING EXPRESSION OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) AND/OR TMPRSS2 | 株式会社 バイオミメティクスシンパシーズ | 2022-08-04 | — | — | WO | disclosed |
| CN-106831375-B | Chalcone compound with anti-tumor activity and preparation method and application thereof | 哈尔滨医科大学 | 2020-11-13 | — | — | CN | disclosed |
| CN-109890376-A | Composition is used in PGC-1 α activation | 三得利控股株式会社 | 2019-06-14 | — | — | CN | disclosed |
| CN-109890378-A | FOXO1 activity-inhibiting composition | 三得利控股株式会社 | 2019-06-14 | — | — | CN | disclosed |
| US-20190008797-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-01-10 | — | — | US | disclosed |
| WO-2017132135-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-08-03 | — | — | WO | disclosed |
| US-20170071902-A1 | NOX INHIBITOR AND NFkB INHIBITOR CONTAINING METHOXYFLAVONE | SUNTORY HOLDINGS LIMITED (JP) | 2017-03-16 | — | — | US | disclosed |
| WO-2007115181-A9 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEM CO (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | EASTMAN CHEMICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| WO-2007115181-A2 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | ABCC4, NCOA4, NR4A3 | MAOB 1213/4885AR 152/4885NR1H4 32/4885 |
| US-20190008797-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | ESRRG, GPER1, ESR2 | MAOB 3735/4885AR 143/4885NR1H4 46/4885 |
| US-20170071902-A1 | NOX INHIBITOR AND NFkB INHIBITOR CONTAINING METHOXYFLAVONE | NOX1, NFKBIA, NOX5 | MAOB 125/4885AR 3610/4885NR1H4 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.